AMERICAN JOURNAL OF GASTROENTEROLOGY, cilt.104, sa.10, ss.2449-2457, 2009 (SCI-Expanded)
OBJECTIVES: Treatment with pegylated interferon (PEG-IFN) alpha-2b results in hepatitis B e antigen (HBeAg) loss in 36% of patients at 6 months post treatment. The aim of this study was to determine whether a long-term response to PEG-IFN is dependent on the timing of HBeAg loss.